Search
Enfortumab vedotin
go.drugbank.com/drugs/DB13007ApprovedInvestigational[L10836] Enfortumab vedotin was later approved by the European Commission on April 13, 2022.[L42000] … Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers.
Benzyl benzoate
go.drugbank.com/drugs/DB00676ApprovedBenzyl benzoate is lethal to this mite and so is useful in the treatment of scabies. It is also used to treat lice infestation of the head and body.
Categories: Compounds used in a research, industrial, or household settingTrimetrexate
go.drugbank.com/drugs/DB01157ApprovedIt is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Evolocumab
go.drugbank.com/drugs/DB09303ApprovedInvestigationalEvolocumab is designed to bind to PCSK9 and inhibit PCSK9 from binding to LDL receptors on the liver surface, resulting in more LDL receptors on the surface of the liver to remove LDL-C from the blood. … Evolocumab is the second PCSK9 inhibitor on the market, first being alirocumab.
Products: REPATHA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 140MG/ML, Repatha Solution for Injection in Pre-filled Syringe 140mg/mL (evolocumab)Acetic acid
go.drugbank.com/drugs/DB03166ApprovedInvestigational(Stedman, 26th ed) Acetic acid otic (for the ear) is an antibiotic that treats infections caused by bacteria or fungus.
Mixtures: AMINOSTERIL N-HEPA 8%, AMINOSTERIL N-HEPA 500 ML SOLUSYONCategories: Compounds used in a research, industrial, or household settingParaldehyde
go.drugbank.com/drugs/DB09117ApprovedWithdrawnParaldehyde is used as an ingredient in some cough medicines as an expectorant, but its efficacy for this indication has not been confirmed and its use as an expectorant may possibly be due to a placebo … Paraldehyde was initially introduced into medical practice in the United Kingdom in 1882 by the Italian physician Vincenzo Cervello.
Zilganersen
go.drugbank.com/drugs/DB18161ApprovedInvestigational[L64096] Alexander disease is caused by variants in the *GFAP* gene that lead to overproduction and toxic accumulation of GFAP in astrocytes, and dysfunction in astrocytes can over time damage neurons … [L64096] The FDA approved zilganersen on September 3, 2026 for the treatment of Alexander disease in pediatric and adult patients, making it the first and only disease-modifying treatment for the condition
Delandistrogene moxeparvovec
go.drugbank.com/drugs/DB16802ApprovedInvestigational[L47026] DMD is an X-linked genetic disorder characterized by mutations in the dystrophin gene, leading to a deficiency in functional dystrophin protein. … [A260256] DMD tends to be more prevalent in males.
Eflornithine
go.drugbank.com/drugs/DB06243ApprovedInvestigationalWithdrawn[A262823,L49318] Subsequently, on December 14, 2023, the FDA approved eflornithine again but under the brand name IWILFIN as an oral maintenance therapy to reduce the risk of relapse in adult and pediatric … a 68% reduction in the risk of death were observed.
Sonidegib
go.drugbank.com/drugs/DB09143ApprovedInvestigationalSonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.
Synonyms: N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridin-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide